Logo image of BLFS

BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLFS - US09062W2044 - Common Stock

25.47 USD
+0.4 (+1.6%)
Last: 12/22/2025, 5:26:53 PM
25.47 USD
0 (0%)
After Hours: 12/22/2025, 5:26:53 PM
Fundamental Rating

5

BLFS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability. BLFS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year BLFS was profitable.
In the past year BLFS had a positive cash flow from operations.
BLFS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
BLFS Yearly Net Income VS EBIT VS OCF VS FCFBLFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

BLFS's Return On Assets of -0.82% is in line compared to the rest of the industry. BLFS outperforms 59.65% of its industry peers.
With a decent Return On Equity value of -0.91%, BLFS is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -0.82%
ROE -0.91%
ROIC N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
BLFS Yearly ROA, ROE, ROICBLFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

BLFS's Gross Margin of 70.02% is amongst the best of the industry. BLFS outperforms 92.98% of its industry peers.
In the last couple of years the Gross Margin of BLFS has remained more or less at the same level.
BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
BLFS Yearly Profit, Operating, Gross MarginsBLFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLFS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLFS has more shares outstanding
Compared to 1 year ago, BLFS has an improved debt to assets ratio.
BLFS Yearly Shares OutstandingBLFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BLFS Yearly Total Debt VS Total AssetsBLFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 18.16 indicates that BLFS is not in any danger for bankruptcy at the moment.
The Altman-Z score of BLFS (18.16) is better than 100.00% of its industry peers.
BLFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.16
ROIC/WACCN/A
WACC10.86%
BLFS Yearly LT Debt VS Equity VS FCFBLFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

BLFS has a Current Ratio of 4.66. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BLFS (4.66) is better than 75.44% of its industry peers.
A Quick Ratio of 3.64 indicates that BLFS has no problem at all paying its short term obligations.
The Quick ratio of BLFS (3.64) is better than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.64
BLFS Yearly Current Assets VS Current LiabilitesBLFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.36%, which is quite impressive.
The Revenue for BLFS has decreased by -24.98% in the past year. This is quite bad
The Revenue has been growing by 24.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%

3.2 Future

The Earnings Per Share is expected to grow by 29.91% on average over the next years. This is a very strong growth
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.63% yearly.
EPS Next Y32.33%
EPS Next 2Y47.08%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue Next Year-9.14%
Revenue Next 2Y1.83%
Revenue Next 3Y8.38%
Revenue Next 5Y15.63%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BLFS Yearly Revenue VS EstimatesBLFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
BLFS Yearly EPS VS EstimatesBLFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 101.88 indicates a quite expensive valuation of BLFS.
BLFS's Price/Earnings ratio is in line with the industry average.
BLFS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.61.
A Price/Forward Earnings ratio of 305.75 indicates a quite expensive valuation of BLFS.
BLFS's Price/Forward Earnings is on the same level as the industry average.
BLFS is valuated expensively when we compare the Price/Forward Earnings ratio to 24.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 101.88
Fwd PE 305.75
BLFS Price Earnings VS Forward Price EarningsBLFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

BLFS's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 228.09
BLFS Per share dataBLFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLFS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 40.10% in the coming years.
PEG (NY)3.15
PEG (5Y)N/A
EPS Next 2Y47.08%
EPS Next 3Y40.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLFS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOLIFE SOLUTIONS INC

NASDAQ:BLFS (12/22/2025, 5:26:53 PM)

After market: 25.47 0 (0%)

25.47

+0.4 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners103.58%
Inst Owner Change-2.65%
Ins Owners2.07%
Ins Owner Change-1.39%
Market Cap1.23B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price Target32.74 (28.54%)
Short Float %6.19%
Short Ratio8.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)2.56%
PT rev (3m)2.56%
EPS NQ rev (1m)-60%
EPS NQ rev (3m)-199.85%
EPS NY rev (1m)6.02%
EPS NY rev (3m)-16.09%
Revenue NQ rev (1m)-2.27%
Revenue NQ rev (3m)-9.5%
Revenue NY rev (1m)-3.96%
Revenue NY rev (3m)-4.28%
Valuation
Industry RankSector Rank
PE 101.88
Fwd PE 305.75
P/S 13.81
P/FCF N/A
P/OCF 72.81
P/B 3.47
P/tB 9.15
EV/EBITDA 228.09
EPS(TTM)0.25
EY0.98%
EPS(NY)0.08
Fwd EY0.33%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.37%
SpS1.84
BVpS7.35
TBVpS2.78
PEG (NY)3.15
PEG (5Y)N/A
Graham Number6.43
Profitability
Industry RankSector Rank
ROA -0.82%
ROE -0.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.02%
FCFM N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 298.5%
Cap/Sales 19.51%
Interest Coverage N/A
Cash Conversion 353.72%
Profit Quality N/A
Current Ratio 4.66
Quick Ratio 3.64
Altman-Z 18.16
F-Score6
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y32.33%
EPS Next 2Y47.08%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-9.14%
Revenue Next 2Y1.83%
Revenue Next 3Y8.38%
Revenue Next 5Y15.63%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year325.11%
EBIT Next 3Y89.24%
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%

BIOLIFE SOLUTIONS INC / BLFS FAQ

What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BLFS.


What is the valuation status for BLFS stock?

ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.


Can you provide the profitability details for BIOLIFE SOLUTIONS INC?

BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.


What is the financial health of BIOLIFE SOLUTIONS INC (BLFS) stock?

The financial health rating of BIOLIFE SOLUTIONS INC (BLFS) is 8 / 10.


Can you provide the dividend sustainability for BLFS stock?

The dividend rating of BIOLIFE SOLUTIONS INC (BLFS) is 0 / 10 and the dividend payout ratio is 0%.